omniture
Ascletis Pharma Inc./歌礼生物科技(杭州)有限公司

Latest News

Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody

HANGZHOU and SHAOXING, China, Jan. 23, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK...

2020-01-23 09:52 3236
1 ... 45678